HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir
The National Institute for Health and Care Excellence (NICE) has recommended against reimbursement for Gilead’s twice-a-year PrEP medication lenacapavir, prompting…
11 Sep 2026
Exegenesis Bio and Modalis sign research deal for Duchenne therapy
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD). The agreement involves the use of…
11 Sep 2026
ABEC to expand global manufacturing network with new Wilson facility
ABEC is set to open a new manufacturing facility in Wilson, North Carolina, US, expanding its network for biopharmaceutical process equipment and consumables. A ribbon-cutting ceremony to mark the opening…
10 Sep 2026
Encoded secures $275m for Dravet syndrome gene therapy
Encoded Therapeutics has raised $275m in a Series F financing round to advance development of its disease-modifying therapy (DMT) for Dravet syndrome, with an eye also on initiating clinical trials…
10 Sep 2026
Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion
Bayer has landed an accelerated US approval for its non-small cell lung cancer (NSCLC) therapy, Hyrnuo (sevabertinib), expanding the drug’s role into the frontline treatment setting within an indication linked…
10 Sep 2026
HHS appoints permanent FDA CBER, CDER heads
The US Department of Health and Human Services (HHS) has selected four senior leaders to assume permanent positions in the US Food and Drug Administration (FDA), bringing some respite to…
10 Sep 2026
Solstice Oncology secures $225m to drive porustobart’s development for cancer
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy. The financing was raised in a Series A round led…